Search Results - "Economidi, A."

Monotherapy and combination therapy with acitretin for mycosis fungoides: results of a retrospective, multicentre study by Nikolaou, V., Patsatsi, A., Sidiropoulou, P., Chlouverakis, G., Kavvalou, E., Koletsa, T., Economidi, A., Georgiou, E., Papadavid, E., Rigopoulos, D., Stratigos, A.J., Kruger‐Krasagakis, S.E.

“…Background Retinoids have long been used in the treatment of cutaneous T‐cell lymphomas. However, data on acitretin use for mycosis fungoides (MF) are very…”
Get full text

Prognostic indicators for mycosis fungoides in a Greek population by Nikolaou, V., Papadavid, E., Patsatsi, A., Siakantaris, M., Economidi, A., Marinos, L., Koletsa, T., Georgiou, E., Pappa, V., Stratigos, A., Antoniou, C.

“…Summary Background Mycosis fungoides (MF) is an indolent cutaneous lymphoma with excellent prognosis at early stages and much poorer outcome during disease…”
Get full text

Mycosis fungoides in the era of antitumour necrosis factor-α treatments by Nikolaou, V., Papadavid, E., Economidi, A., Marinos, L., Moustou, E., Karampidou, K., Papadaki, T., Stratigos, A., Antoniou, C.

Get full text

Psoriasis in patients with mycosis fungoides: a clinicopathological study of 25 patients by Nikolaou, V., Marinos, L., Moustou, E., Papadavid, E., Economidi, A., Christofidou, E., Gerochristou, M., Tasidou, A., Economaki, E., Stratigos, A., Antoniou, C.

“…Background It has been reported that patients with psoriasis are at increased risk for developing lymphoma including cutaneous T‐cell lymphomas (CTCL)…”
Get full text

Brentuximab induced CD30+ cutaneous lymphoma responded to anti‐PD1 treatment by Nikolaou, V., Iliakis, T., Marinos, L., Economidi, A., Panayiotidis, P., Rigopoulos, D., Stratigos, AJ

Get full text

PUVA plus interferon alpha 2b in the treatment of advanced or refractory to PUVA early stage mycosis fungoides: a case series by Nikolaou, V, Siakantaris, M P, Vassilakopoulos, T P, Papadavid, E, Stratigos, A, Economidi, A, Marinos, L, Papadaki, T, Antoniou, C

“…Background The combination of PUVA with variable doses of systemically administered interferon alpha 2b (IFN- alpha 2b) reduces the number of PUVA treatments…”
Get full text

PUVA plus interferon α2b in the treatment of advanced or refractory to PUVA early stage mycosis fungoides: a case series by Nikolaou, V, Siakantaris, MP, Vassilakopoulos, TP, Papadavid, E, Stratigos, A, Economidi, A, Marinos, L, Papadaki, T, Antoniou, C

“…Background  The combination of PUVA with variable doses of systemically administered interferon α2b (IFN‐α2b) reduces the number of PUVA treatments and the…”
Get full text

Acrokeratosis verruciformis of Hopf (Hopf disease): case report and review of the literature by Rallis, E, Economidi, A, Papadakis, P, Verros, C

“…Acrokeratosis verruciformis of Hopf is an autosomal dominant genodermatosis usually presenting with multiple planar wart-like lesions, typically observed on…”
Get full text

Brentuximab induced CD 30 + cutaneous lymphoma responded to anti‐ PD 1 treatment by Nikolaou, V., Iliakis, T., Marinos, L., Economidi, A., Panayiotidis, P., Rigopoulos, D., Stratigos, AJ

Get full text

P106 Mycosis fungoides with a CD56+ immunophenotype: report of 2 cases by Nikolaou, V., Marinos, L., Stratigos, A., Economidi, A., Papadaki, T., Katsambas, A., Antoniou, C.

Get full text

P107 Clinical, immunophenotypical and molecular analysis of a series of patients with poikilodermatous mycosis fungoides by Nikolaou, V., Economidi, A., Stratigos, A., Marinos, L., Miniati, A., Papadaki, T., Katsambas, A., Antoniou, C.

Get full text

Brentuximab induced CD30+ cutaneous lymphoma responded to anti-PD1 treatment by Nikolaou, V, Iliakis, T, Marinos, L, Economidi, A, Panayiotidis, P, Rigopoulos, D, Stratigos, A J

Get full text